ArticleJournal of epilepsy research2026
Melatonin Prolonged-Release May Improve Insomnia and Depression in Epilepsy Patients.
Article in Journal of epilepsy research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Purpose: Insomnia is a common sleep disorder that is highly prevalent among patients with epilepsy. Despite the known benefits of melatonin for insomnia and its potential anticonvulsive effects, clinical evidence regarding its efficacy in epilepsy patients with comorbid insomnia remains limited. This pilot study aimed to evaluate the efficacy and safety of prolonged-release (PR) formulation of melatonin in epilepsy patients with insomnia. Methods: We prospectively enrolled 34 adult patients with epilepsy from March 2024 to February 2025. The insomnia severity index (ISI) and the Korean version of the Neurological Disorders of Depression Inventory for Epilepsy (K-NDDI-E) were assessed before and after 12 weeks of melatonin PR intake. Data were analyzed using the Wilcoxon signed-rank test. Changes in seizure status before and after treatment were analyzed using McNemar's test. Results: A total of 25 patients (nine males, mean age 53.5±11.6 years) completed the study. Of these, 23 had focal-onset seizures and two had generalized-onset seizures. After 12 weeks of treatment, ISI scores significantly improved from 16.0±4.4 to 12.2±5.2 ( Conclusions: Our findings demonstrate that melatonin PR effectively improves both sleep quality and depression in epilepsy patients with insomnia. These results suggest that melatonin PR could be a potential therapeutic option for managing comorbid insomnia and depression in patients with epilepsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.